NCT04963088 2025-06-26
TALENT
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Completed
Clinical Trials
8 trialsNCT04278222 2024-07-10
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT04891900 2024-07-08
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Phase NA Active not recruiting
NCT05029102 2024-02-12
TAS-102 and Anlotinib in ≥3 Lines mGC
Zhejiang University
Phase 2 Unknown
NCT06222944 2024-01-25
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Peking University
Phase 2 Not yet recruiting
NCT05385900 2022-05-23
ICTCPTLAGC
Xijing Hospital
Phase NA Unknown
NCT04777162 2021-03-04
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
Phase 2 Unknown
NCT02461407 2017-12-29
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown